Download presentation
Presentation is loading. Please wait.
1
Omega-3s vs Pure EPA in Clinical Practice
2
Rationale for the Use of Fish Oil
3
Primary and Secondary CVD Prevention Trials Evaluating Treatment of TGs
4
Rationale for the Use of Highly Purified EPA
5
REDUCE-IT Study Design
6
REDUCE-IT Primary and Secondary Endpoint Results
7
REDUCE-IT Prespecified Hierarchical Testing
8
REDUCE-IT CV Benefit of EPA Independent of LDL-C Levels
9
Ischemic Event Reduction With Icosapent Ethyl
10
Ischemic Event Reduction With Icosapent Ethyl Statistical Handling
11
REDUCE-IT Analysis Reduction of First and Subsequent Events
12
First and Total Events Over the Years
13
Primary Composite Endpoint Total Endpoint Events by Baseline TG Tertiles
14
REDUCE-IT Change in Biomarkers After 1 Year
15
Risk Differences With Icosapent Ethyl
16
Safety Results
17
REDUCE-IT Serious Bleeding
18
Medications Taken at Baseline
19
Membrane Stabilization
20
Effects of EPA on Plaque Progression
21
Prescription-Only Omega-3s vs Dietary Supplement Omega-3s
22
2018 Cholesterol Guidelines Secondary Prevention in Patients With Clinical ASCVD
23
Collaborative Care
24
Conclusion
25
Abbreviations
26
Abbreviations (cont)
27
Abbreviations (cont)
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.